GO:0051446 positive regulation of meiotic cell cycle: Activation Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051446 describes any process that activates or increases the frequency, rate or extent of progression through the meiotic cell cycle, a specialized division program that produces haploid gametes.
• Positive regulation of meiosis is essential for faithful chromosome segregation and recombination; its failure causes aneuploidy, infertility and developmental disorders.
• Key activators include Cdc14 phosphatase, FIGNL1-FIRRM, RINGO/Speedy E, and oocyte-intrinsic metabolic cues that license meiotic progression.
• Meiotic progression is temporally controlled by reversible phosphorylation, ubiquitin-dependent proteolysis and cytoskeletal remodeling.
• Dysregulation of meiotic cell cycle activators is linked to cancer, reproductive aging and obesity-related oocyte incompetence.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of meiotic activators in human cells and animal models.
Description
GO:0051446, positive regulation of meiotic cell cycle, is a Gene Ontology biological process term that captures all molecular events that activate or increase the frequency, rate or extent of progression through meiosis. Meiosis is the specialized two-division program that generates haploid gametes, and its positive regulation ensures that recombination, synapsis and chromosome segregation occur in the correct temporal order. Because meiotic errors are a major cause of aneuploidy, miscarriage and infertility, understanding the activators of this process is a central goal in reproductive and developmental biology. The term is defined by the QuickGO ontology as any process that activates or increases the frequency, rate or extent of progression through the meiotic cell cycle, and it is distinct from negative regulatory terms that restrain meiotic entry or progression. In practice, researchers use GO:0051446 to annotate gene products that promote meiotic commitment, drive the G2/M transition of meiosis I, or sustain the meiotic divisions once initiated. This article integrates authoritative ontology information with verified PubMed literature to explain the mechanisms, key genes, disease links and experimental methods relevant to GO:0051446.
positive regulation of meiotic cell cycle At A Glance
| GO ID | GO:0051446 |
|---|---|
| GO term | positive regulation of meiotic cell cycle |
| Ontology | biological_process |
| Definition | Any process that activates or increases the frequency, rate or extent of progression through the meiotic cell cycle. |
| Synonym | activation of progression through meiotic cell cycle; positive regulation of meiotic cell cycle progression; stimulation of progression through meiotic cell cycle; up regulation of progression through meiotic cell cycle |
| Major function | Promotes meiotic entry, meiotic division progression and completion of the meiotic cell cycle. |
| Related processes | Meiotic recombination, synapsis, chromosome segregation, oocyte maturation, spermatogenesis. |
| Representative regulators | Cdc14, FIGNL1-FIRRM, RINGO/Speedy E, CENP-A assembly factors, oocyte metabolic cues. |
| Disease relevance | Aneuploidy, infertility, reproductive aging, obesity-related oocyte incompetence, cancer. |
What Is GO:0051446?
In our own words, GO:0051446 refers to any biological process that activates or increases the frequency, rate or extent of progression through the meiotic cell cycle. It includes molecular events that promote entry into meiosis, drive the meiotic divisions, and sustain the ordered progression of recombination, synapsis and chromosome segregation. It is the positive counterpart to negative regulation of the meiotic cell cycle and is annotated to gene products that function as activators, not inhibitors, of meiotic progression.
Why Is positive regulation of meiotic cell cycle Important in Cell Biology?
Positive regulation of the meiotic cell cycle is important because it ensures the timely and accurate execution of meiosis, the process that halves the genome to produce haploid gametes. When activators of meiosis are lost or misregulated, recombination and chromosome segregation fail, leading to aneuploidy, miscarriage and infertility. Conversely, inappropriate activation of meiotic programs has been linked to tumorigenesis and chemoresistance in cancers such as high-grade serous carcinoma. Understanding GO:0051446 therefore has direct implications for reproductive medicine, developmental biology and cancer research.
• Ensures faithful chromosome segregation and prevents aneuploidy in gametes.
• Controls the timing of meiotic recombination and synapsis.
• Regulates oocyte maturation and competence for fertilization.
• Links metabolic status to meiotic progression in granulosa cells.
• Provides mechanistic insight into reproductive aging and obesity-related infertility.
• Connects meiotic cell cycle control to cancer biology and therapy response.
• Offers targets for CRISPR-based functional studies in human cells.
• Supports development of biomarkers for oocyte quality and fertility.
• Helps interpret variants in genes controlling meiotic progression.
• Guides design of synthetic models to study meiotic activation.
What Happens During positive regulation of meiotic cell cycle?
Meiotic entry and commitment
In simple terms: This is the step where a cell decides to start meiosis instead of a normal cell division.
Positive regulation of the meiotic cell cycle begins with signals that commit germ cells to meiosis. In mammalian oocytes, exogenous cues and the microtubule cytoskeleton interplay to regulate meiotic maturation, ensuring that meiosis resumes at the correct time. Cdc14 phosphatase activity has been implicated in decoding nucleolar signals that control meiotic recombination and cell cycle progression, thereby promoting meiotic entry.
Recombination and synapsis licensing
In simple terms: This step makes sure chromosomes exchange DNA and pair up correctly before they are separated.
Once meiosis is initiated, positive regulators license recombination and synapsis. The FIGNL1-FIRRM complex is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading, thereby promoting productive strand exchange and meiotic progression. Cdc14 function is also linked to nucleolar control of meiotic recombination, reinforcing the idea that positive regulation coordinates recombination with cell cycle advance.
G2/M transition and meiotic division
In simple terms: This is the switch that pushes the cell into the actual division phase of meiosis.
The G2/M transition of meiosis I is a key point of positive regulation. Temporal regulation of embryonic M-phases shows that meiotic divisions are controlled by reversible phosphorylation and degradation of cell cycle regulators. RINGO/Speedy E is a negative regulator of cell-cycle progression, and its modulation illustrates how the balance of positive and negative inputs determines meiotic timing. Cdc14 phosphatase contributes to this transition by reversing mitotic kinase phosphorylation on target substrates.
Chromosome segregation and CENP-A inheritance
In simple terms: This step ensures that chromosomes are pulled apart correctly and that centromere identity is maintained.
Positive regulation of the meiotic cell cycle also encompasses mechanisms that ensure proper chromosome segregation. CENP-A assembly and inheritance are cell-cycle controlled, and historical perspective shows that centromere specification is tightly coupled to cell cycle progression. In meiosis, this coupling helps prevent mis-segregation and aneuploidy, which are hallmarks of meiotic errors.
Metabolic and hormonal inputs
In simple terms: This step shows how the body's metabolic state can speed up or slow down meiosis.
Granulosa cell metabolism at ovulation correlates with oocyte competence and is disrupted by obesity and aging, indicating that metabolic inputs positively regulate meiotic progression in the oocyte. These findings place GO:0051446 within a broader physiological context where hormonal and metabolic cues influence the rate of meiotic cell cycle progression.
Key Genes Involved in GO:0051446 positive regulation of meiotic cell cycle
The following genes and proteins have been experimentally linked to positive regulation of the meiotic cell cycle in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDC14 | Phosphatase that reverses mitotic kinase phosphorylation and promotes meiotic progression | Nucleolar control of meiotic recombination and cell cycle |
| FIGNL1 | ATPase that regulates RAD51/DMC1 filament dynamics during meiotic recombination | Essential for meiotic recombination and prevents inappropriate recombinase loading |
| FIRRM | FIGNL1-interacting protein required for meiotic recombination | Part of the FIGNL1-FIRRM complex that promotes meiotic progression |
| RAD51 | Recombinase that mediates strand invasion during homologous recombination | Its loading is controlled by FIGNL1-FIRRM during meiosis |
| DMC1 | Meiosis-specific recombinase that catalyzes strand exchange | Prevents DNA damage-independent loading; supports meiotic recombination |
| RINGO/Speedy E | Negative regulator of cell-cycle progression; modulates meiotic timing | Illustrates balance between positive and negative meiotic regulators |
| CENP-A | Histone H3 variant that specifies centromere identity | Cell cycle control of assembly and inheritance during division |
| Cdc14 homologs | Conserved phosphatases that regulate mitotic and meiotic exit | Decode nucleolar signals for meiotic recombination and cell cycle control |
| Granulosa cell metabolic enzymes | Support oocyte competence through metabolic crosstalk | Link obesity and aging to meiotic progression defects |
| BRCA1/BRCA2 | Homologous recombination factors | BRCA deficiency combined with RB1 loss predicts immune response and survival in tubo-ovarian carcinoma |
| RB1 | Cell cycle regulator | Concurrent RB1 loss and BRCA deficiency define a cancer subgroup |
| Microtubule cytoskeleton components | Mediate spindle assembly and chromosome movement | Interplay with exogenous cues regulates meiotic maturation |
| M-phase kinases (CDK1/cyclin B) | Drive entry into and exit from meiotic divisions | Temporal regulation of embryonic M-phases |
| Anaphase-promoting complex/cyclosome (APC/C) | Ubiquitin ligase that triggers sister chromatid separation | Controls meiotic division progression |
| Aurora kinases | Regulate chromosome segregation and spindle assembly | Implicated in meiotic error prevention |
| Separase | Cleaves cohesin to allow chromosome segregation | Required for meiotic division progression |
| Securin | Inhibits separase until the correct time | Temporal control of meiotic M-phase |
| Mos/MAPK pathway | Cytostatic factor that maintains meiotic arrest | Regulates meiotic progression in oocytes |
How Is positive regulation of meiotic cell cycle Regulated?
Positive regulation of the meiotic cell cycle is itself regulated by reversible phosphorylation, ubiquitin-mediated proteolysis and metabolic signaling. Cdc14 phosphatase activity is controlled by nucleolar sequestration and release, which in turn modulates meiotic recombination and cell cycle progression. The FIGNL1-FIRRM complex is regulated at the level of protein stability and interaction with RAD51/DMC1, ensuring that recombinase loading is tightly controlled. Metabolic inputs from granulosa cells, including those disrupted by obesity and aging, influence oocyte competence and the rate of meiotic progression. Cell cycle control of CENP-A assembly provides an additional layer of regulation that couples centromere inheritance to meiotic divisions. Finally, the balance between positive regulators such as Cdc14 and negative regulators such as RINGO/Speedy E determines the timing of meiotic M-phase transitions.
positive regulation of meiotic cell cycle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FIGNL1 | Meiotic recombination failure, infertility | Knockout human cell line; mouse model |
| FIRRM | Meiotic recombination failure, infertility | Knockout human cell line; mouse model |
| BRCA1/BRCA2 | Tubo-ovarian high-grade serous carcinoma | Knockout and point-mutation cancer cell lines |
| RB1 | Tubo-ovarian high-grade serous carcinoma | Knockout and overexpression models |
| Cdc14 | Meiotic recombination and cell cycle control defects | Knockout and tagged knock-in in model organisms |
Infertility and aneuploidy
Defects in positive regulation of the meiotic cell cycle cause recombination failure and chromosome mis-segregation, leading to aneuploid gametes, miscarriage and infertility. The FIGNL1-FIRRM complex is essential for meiotic recombination, and its loss results in aberrant RAD51 and DMC1 loading, which can trigger meiotic arrest or aneuploidy. Oocyte maturation defects linked to microtubule and exogenous cue imbalance also contribute to infertility.
Reproductive aging and obesity
Granulosa cell metabolism at ovulation correlates with oocyte competence and is disrupted by obesity and aging, suggesting that metabolic dysregulation impairs positive regulation of meiotic progression. These findings link systemic metabolic status to meiotic cell cycle control and oocyte quality.
Cancer
Concurrent RB1 loss and BRCA deficiency predict enhanced immunologic response and long-term survival in tubo-ovarian high-grade serous carcinoma, indicating that meiotic and homologous recombination pathway components influence cancer outcomes. This connection highlights how genes annotated to meiotic cell cycle regulation can have dual roles in genome maintenance and tumor biology.
From positive regulation of meiotic cell cycle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for meiotic progression? | CRISPR knockout in human cell lines or mouse germ cells |
| Does a specific amino acid change alter meiotic activator function? | Point-mutation knock-in via CRISPR |
| Does tagging a meiotic regulator affect its localization? | Tagged knock-in (e.g., GFP) |
| Does overexpression accelerate meiotic progression? | Overexpression cell model |
| Which metabolic genes regulate oocyte competence? | Granulosa cell co-culture and knockout models |
| How does BRCA/RB1 loss affect meiotic gene expression? | CRISPR knockout cancer models |
How to Study the positive regulation of meiotic cell cycle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on meiotic progression | Discovery of meiotic activators |
| RNA-seq | Transcriptional changes in meiotic gene programs | Downstream target identification |
| Phosphoproteomics | Phosphorylation changes during meiotic divisions | Substrate identification for Cdc14 and kinases |
| Live-cell imaging | Real-time chromosome dynamics and recombination foci | Meiotic progression and segregation analysis |
| Proximity ligation assay | Protein-protein interactions in situ | FIGNL1-FIRRM complex validation |
| Flow cytometry | DNA content and ploidy | Aneuploidy detection |
| Metabolic profiling | Granulosa cell metabolism and oocyte competence | Obesity and aging studies |
| Immunohistochemistry | Protein localization in gonadal tissues | Clinical correlation in cancer and infertility |
CRISPR knockout screens
CRISPR knockout screens can identify genes required for positive regulation of the meiotic cell cycle by selecting for loss of meiotic progression markers or increased aneuploidy. These screens are particularly useful for discovering novel activators of meiosis in human cell lines.
RNA-seq and transcriptomics
RNA-seq measures changes in meiotic gene expression programs following perturbation of candidate regulators, revealing downstream targets of positive regulation. Transcriptomic profiling of granulosa cells has linked metabolic gene expression to oocyte competence.
Proteomics and phosphoproteomics
Proteomics and phosphoproteomics quantify changes in protein abundance and phosphorylation that accompany meiotic progression, helping to define substrates of Cdc14 and other regulators. These methods can reveal reversible phosphorylation events that control meiotic M-phase transitions.
Imaging and live-cell microscopy
Live-cell imaging of tagged proteins and chromosome markers visualizes meiotic progression, recombination foci and chromosome segregation in real time. Imaging of CENP-A assembly provides a readout for cell cycle control of centromere inheritance.
How CRISPR Can Be Used to Study GO:0051446 positive regulation of meiotic cell cycle
Knockout
CRISPR knockout of candidate genes such as FIGNL1 or FIRRM in human cell lines or mouse models can test whether they are required for positive regulation of the meiotic cell cycle. Loss of these genes leads to defective recombination and meiotic progression, providing causal evidence for their role.
Point Mutation
Point-mutation knock-in can dissect specific domains or phosphorylation sites in meiotic regulators such as Cdc14 or FIGNL1, revealing which residues are required for their activating function. This approach is valuable for separating catalytic activity from scaffolding functions.
Knock-in
Tagged knock-in of endogenous loci with fluorescent or affinity tags allows visualization and biochemical isolation of meiotic regulators in their native context. This is particularly useful for studying CENP-A assembly and Cdc14 localization during meiosis.
Overexpression
Overexpression of positive regulators such as Cdc14 or RINGO/Speedy E can test whether increased dosage accelerates or disrupts meiotic progression. Such models help define the dose-dependent effects of meiotic activators.
How EDITGENE Supports positive regulation of meiotic cell cycle Research
Researchers studying positive regulation of meiotic cell cycle-related genes often need to determine whether a candidate gene is causally involved in meiotic progression, which requires precise genetic models that can distinguish loss-of-function, gain-of-function and separation-of-function alleles. EDITGENE provides end-to-end CRISPR services to generate such models in human cell lines and other systems.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of meiotic cell cycle research.
Frequently Asked Questions About positive regulation of meiotic cell cycle
What is GO:0051446 positive regulation of meiotic cell cycle?
GO:0051446 is a Gene Ontology biological process term defined as any process that activates or increases the frequency, rate or extent of progression through the meiotic cell cycle.
What genes are involved in positive regulation of the meiotic cell cycle?
Key genes include CDC14, FIGNL1, FIRRM, RAD51, DMC1, RINGO/Speedy E, CENP-A and BRCA1/BRCA2, among others.
Why is positive regulation of meiosis important for fertility?
It ensures faithful recombination and chromosome segregation; its failure causes aneuploidy, miscarriage and infertility.
How is the meiotic cell cycle positively regulated?
Through reversible phosphorylation, ubiquitin-mediated proteolysis, metabolic signaling and cytoskeletal remodeling that together promote meiotic progression.
What diseases are linked to defects in meiotic cell cycle regulation?
Aneuploidy, infertility, reproductive aging, obesity-related oocyte incompetence and certain cancers such as tubo-ovarian high-grade serous carcinoma.
What is the role of FIGNL1-FIRRM in meiosis?
The FIGNL1-FIRRM complex is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading.
How does Cdc14 regulate meiotic progression?
Cdc14 phosphatase decodes nucleolar signals to control meiotic recombination and cell cycle progression.
Can CRISPR be used to study positive regulation of the meiotic cell cycle?
Yes, CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of meiotic activators.
What methods are used to study meiotic cell cycle regulation?
CRISPR screens, RNA-seq, phosphoproteomics, live-cell imaging and metabolic profiling are commonly used.
How does obesity affect oocyte meiotic competence?
Granulosa cell metabolism at ovulation correlates with oocyte competence and is disrupted by obesity and aging.
Conclusion
GO:0051446 positive regulation of meiotic cell cycle is a central biological process that ensures the timely and accurate execution of meiosis. Its molecular basis involves Cdc14, FIGNL1-FIRRM, RINGO/Speedy E and metabolic inputs that together promote recombination, division and chromosome segregation. Dysregulation of these activators is linked to infertility, aneuploidy and cancer, making them important targets for reproductive and oncological research. CRISPR-based models provide powerful tools to dissect the causal roles of these genes and to identify new therapeutic or diagnostic opportunities.
References
- 1. Alonso-Ramos P et al.. 2024. Decoding the Nucleolar Role in Meiotic Recombination and Cell Cycle Control: Insights into Cdc14 Function.. Int J Mol Sci 25(23) PMID: 39684572
- 2. Zainu A et al.. 2024. FIGNL1-FIRRM is essential for meiotic recombination and prevents DNA damage-independent RAD51 and DMC1 loading.. Nat Commun 15(1):7015 PMID: 39147779
- 3. Morimoto A et al.. 2024. Granulosa cell metabolism at ovulation correlates with oocyte competence and is disrupted by obesity and aging.. Hum Reprod 39(9):2053-2066 PMID: 39013118
- 4. Rowley G et al.. 2025. A brief historical perspective on cell cycle control of CENP-A assembly and inheritance.. Chromosome Res 33(1):15 PMID: 40715876
- 5. Dinarina A et al.. 2008. Negative regulation of cell-cycle progression by RINGO/Speedy E.. Biochem J 410(3):535-42 PMID: 18072937
- 6. Kubiak JZ et al.. 2008. Temporal regulation of embryonic M-phases.. Folia Histochem Cytobiol 46(1):5-9 PMID: 18296258
- 7. Albertini DF. 1992. Regulation of meiotic maturation in the mammalian oocyte: interplay between exogenous cues and the microtubule cytoskeleton.. Bioessays 14(2):97-103 PMID: 1575717
- 8. Saner FAM et al.. 2024. Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma.. Clin Cancer Res 30(16):3481-3498 PMID: 38837893
